{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T03:17:06Z","timestamp":1792552626097,"version":"4.5.0"},"reference-count":40,"publisher":"Oxford University Press (OUP)","issue":"3","license":[{"start":{"date-parts":[[2021,12,11]],"date-time":"2021-12-11T00:00:00Z","timestamp":1639180800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,2,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Cocirculation of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and influenza viruses could pose unpredictable risks to health systems globally, with recent studies suggesting more severe disease outcomes in coinfected patients. The initial lack of a readily available coronavirus disease 2019 (COVID-19) vaccine has reinforced the importance of influenza vaccine programs during the COVID-19 pandemic. Live attenuated influenza vaccine (LAIV) is an important tool in protecting against influenza, particularly in children. However, it is unknown whether LAIV administration influences the outcomes of acute SARS-CoV-2 infection or disease. To investigate this, quadrivalent LAIV was administered to ferrets 3 days before or after SARS-CoV-2 infection. LAIV administration did not exacerbate the SARS-CoV-2 disease course or lung pathology with either regimen. In addition, LAIV administered before SARS-CoV-2 infection significantly reduced SARS-CoV-2 replication and shedding in the upper respiratory tract. This study demonstrated that LAIV administration in close proximity to SARS-CoV-2 infection does not exacerbate mild disease and can reduce SARS-CoV-2 shedding.<\/jats:p>","DOI":"10.1093\/infdis\/jiab594","type":"journal-article","created":{"date-parts":[[2021,12,9]],"date-time":"2021-12-09T15:12:01Z","timestamp":1639062721000},"page":"404-412","source":"Crossref","is-referenced-by-count":15,"title":["Sequential Delivery of Live Attenuated Influenza Vaccine and Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) in the Ferret Model Can Reduce SARS-CoV-2 Shedding and Does Not Result in Enhanced Lung Pathology"],"prefix":"10.1093","volume":"225","author":[{"given":"Kathryn A","family":"Ryan","sequence":"first","affiliation":[{"name":"UK Health Security Agency, Porton Down, Salisbury, Wiltshire, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9002-5014","authenticated-orcid":false,"given":"Katarzyna E","family":"Schewe","sequence":"additional","affiliation":[{"name":"Flu-BPD, BioPharmaceutical Development, R&D, AstraZeneca, Liverpool, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan","family":"Crowe","sequence":"additional","affiliation":[{"name":"Flu-BPD, BioPharmaceutical Development, R&D, AstraZeneca, Liverpool, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan A","family":"Fotheringham","sequence":"additional","affiliation":[{"name":"UK Health Security Agency, Porton Down, Salisbury, Wiltshire, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yper","family":"Hall","sequence":"additional","affiliation":[{"name":"UK Health Security Agency, Porton Down, Salisbury, Wiltshire, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Humphreys","sequence":"additional","affiliation":[{"name":"UK Health Security Agency, Porton Down, Salisbury, Wiltshire, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony C","family":"Marriott","sequence":"additional","affiliation":[{"name":"UK Health Security Agency, Porton Down, Salisbury, Wiltshire, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jemma","family":"Paterson","sequence":"additional","affiliation":[{"name":"UK Health Security Agency, Porton Down, Salisbury, Wiltshire, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emma","family":"Rayner","sequence":"additional","affiliation":[{"name":"UK Health Security Agency, Porton Down, Salisbury, Wiltshire, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francisco J","family":"Salguero","sequence":"additional","affiliation":[{"name":"UK Health Security Agency, Porton Down, Salisbury, Wiltshire, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert J","family":"Watson","sequence":"additional","affiliation":[{"name":"UK Health Security Agency, Porton Down, Salisbury, Wiltshire, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine J","family":"Whittaker","sequence":"additional","affiliation":[{"name":"UK Health Security Agency, Porton Down, Salisbury, Wiltshire, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miles W","family":"Carroll","sequence":"additional","affiliation":[{"name":"UK Health Security Agency, Porton Down, Salisbury, Wiltshire, United Kingdom"},{"name":"Nuffield Department of Medicine, Oxford University, Oxford, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oliver","family":"Dibben","sequence":"additional","affiliation":[{"name":"Flu-BPD, BioPharmaceutical Development, R&D, AstraZeneca, Liverpool, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2021,12,11]]},"reference":[{"key":"2022020201071992700_CIT0001","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1093\/ije\/dyab081","article-title":"Interactions between SARS-CoV-2 and influenza, and the impact of coinfection on disease severity: a test-negative design.","volume":"50","author":"Stowe","year":"2021","journal-title":"Int J Epidemiol"},{"key":"2022020201071992700_CIT0002","article-title":"Sequential infection with influenza A virus followed by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) leads to more severe disease and encephalitis in a mouse model of COVID-19.","author":"Clark","year":"2021","journal-title":"bioRxiv"},{"key":"2022020201071992700_CIT0003","doi-asserted-by":"crossref","first-page":"e978","DOI":"10.1093\/cid\/ciaa1747","article-title":"Coinfection by severe acute respiratory syndrome coronavirus 2 and influenza A(H1N1)pdm09 virus enhances the severity of pneumonia in golden Syrian hamsters.","volume":"72","author":"Zhang","year":"2021","journal-title":"Clin Infect Dis"},{"key":"2022020201071992700_CIT0004","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1097\/01.inf.0000237829.66310.85","article-title":"Superior relative efficacy of live attenuated influenza vaccine compared with inactivated influenza vaccine in young children with recurrent respiratory tract infections.","volume":"25","author":"Ashkenazi","year":"2006","journal-title":"Pediatr Infect Dis J"},{"key":"2022020201071992700_CIT0005","doi-asserted-by":"crossref","first-page":"e255","DOI":"10.1093\/cid\/ciaa050","article-title":"Effectiveness of 2 influenza vaccines in nationwide cohorts of Finnish 2-year-old children in the seasons 2015-2016 through 2017-2018.","volume":"71","author":"Baum","year":"2020","journal-title":"Clin Infect Dis"},{"key":"2022020201071992700_CIT0006","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1056\/NEJMoa065368","article-title":"Live attenuated versus inactivated influenza vaccine in infants and young children.","volume":"356","author":"Belshe","year":"2007","journal-title":"N Engl J Med"},{"key":"2022020201071992700_CIT0007","doi-asserted-by":"crossref","first-page":"e181514","DOI":"10.1001\/jamapediatrics.2018.1514","article-title":"Effectiveness of live attenuated vs inactivated influenza vaccines in children during the 2012-2013 through 2015-2016 influenza seasons in Alberta, Canada: a Canadian Immunization Research Network (CIRN) study.","volume":"172","author":"Buchan","year":"2018","journal-title":"JAMA Pediatr"},{"key":"2022020201071992700_CIT0008","doi-asserted-by":"crossref","first-page":"e868","DOI":"10.1542\/peds.2005-1301","article-title":"A pilot study of the effectiveness of a school-based influenza vaccination program.","volume":"116","author":"King","year":"2005","journal-title":"Pediatrics"},{"key":"2022020201071992700_CIT0009","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1016\/j.vaccine.2019.10.071","article-title":"End of season influenza vaccine effectiveness in primary care in adults and children in the United Kingdom in 2018\/19.","volume":"38","author":"Pebody","year":"2020","journal-title":"Vaccine"},{"key":"2022020201071992700_CIT0010","doi-asserted-by":"crossref","first-page":"e023118","DOI":"10.1136\/bmjopen-2018-023118","article-title":"Evaluation of the safety of live attenuated influenza vaccine (LAIV) in children and adolescents with asthma and high-risk conditions: a population-based prospective cohort study conducted in England with the clinical practice research datalink.","volume":"8","author":"Caspard","year":"2018","journal-title":"BMJ Open"},{"key":"2022020201071992700_CIT0011","author":"Centers for Disease Control and Prevention."},{"key":"2022020201071992700_CIT0012","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1016\/j.anai.2017.01.030","article-title":"Live attenuated influenza vaccine use and safety in children and adults with asthma.","volume":"118","author":"Duffy","year":"2017","journal-title":"Ann Allergy Asthma Immunol"},{"key":"2022020201071992700_CIT0013","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1097\/01.inf.0000237797.14283.cf","article-title":"Comparison of the efficacy and safety of live attenuated cold-adapted influenza vaccine, trivalent, with trivalent inactivated influenza virus vaccine in children and adolescents with asthma.","volume":"25","author":"Fleming","year":"2006","journal-title":"Pediatr Infect Dis J"},{"key":"2022020201071992700_CIT0014","doi-asserted-by":"crossref","first-page":"2668","DOI":"10.1016\/j.vaccine.2017.03.082","article-title":"Asthma exacerbations among asthmatic children receiving live attenuated versus inactivated influenza vaccines.","volume":"35","author":"Ray","year":"2017","journal-title":"Vaccine"},{"key":"2022020201071992700_CIT0015","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1016\/j.jaci.2019.12.010","article-title":"Safety of live attenuated influenza vaccine (LAIV) in children with moderate to severe asthma.","volume":"145","author":"Turner","year":"2020","journal-title":"J Allergy Clin Immunol"},{"key":"2022020201071992700_CIT0016","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1016\/j.cmi.2020.06.017","article-title":"Children and SARS-CoV-2 infection: innocent bystanders\u2026until proven otherwise.","volume":"26","author":"Lanari","year":"2020","journal-title":"Clin Microbiol Infect"},{"key":"2022020201071992700_CIT0017","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1001\/jamapediatrics.2020.4095","article-title":"Prevalence of SARS-CoV-2 infection in children without symptoms of coronavirus disease 2019.","volume":"175","author":"Sola","year":"2021","journal-title":"JAMA Pediatr"},{"key":"2022020201071992700_CIT0018","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.jpeds.2020.08.037","article-title":"Pediatric severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2): clinical presentation, infectivity, and immune responses.","volume":"227","author":"Yonker","year":"2020","journal-title":"J Pediatr"},{"key":"2022020201071992700_CIT0019","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1038\/s41541-021-00300-z","article-title":"Defining the root cause of reduced H1N1 live attenuated influenza vaccine effectiveness: low viral fitness leads to inter-strain competition.","volume":"6","author":"Dibben","year":"2021","journal-title":"NPJ Vaccines"},{"key":"2022020201071992700_CIT0020","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1016\/j.chom.2020.03.023","article-title":"Infection and rapid transmission of SARS-CoV-2 in ferrets.","volume":"27","author":"Kim","year":"2020","journal-title":"Cell Host Microbe"},{"key":"2022020201071992700_CIT0021","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1126\/science.abb7015","article-title":"Susceptibility of ferrets, cats, dogs, and other domesticated animals to SARS-coronavirus 2.","volume":"368","author":"Shi","year":"2020","journal-title":"Science"},{"key":"2022020201071992700_CIT0022","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1038\/s41467-020-20439-y","article-title":"Dose-dependent response to infection with SARS-CoV-2 in the ferret model and evidence of protective immunity.","volume":"12","author":"Ryan","year":"2021","journal-title":"Nat Commun"},{"key":"2022020201071992700_CIT0023","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1038\/s41586-020-2196-x","article-title":"Virological assessment of hospitalized patients with COVID-2019.","volume":"581","author":"W\u00f6lfel","year":"2020","journal-title":"Nature"},{"key":"2022020201071992700_CIT0024","doi-asserted-by":"crossref","first-page":"459","DOI":"10.5694\/mja2.50569","article-title":"Isolation and rapid sharing of the 2019 novel coronavirus (SARS-CoV-2) from the first patient diagnosed with COVID-19 in Australia.","volume":"212","author":"Caly","year":"2020","journal-title":"Med Jo Aust"},{"key":"2022020201071992700_CIT0025","doi-asserted-by":"crossref","first-page":"11014","DOI":"10.1128\/JVI.79.17.11014-11021.2005","article-title":"Multiple gene segments control the temperature sensitivity and attenuation phenotypes of ca B\/Ann Arbor\/1\/66.","volume":"79","author":"Hoffmann","year":"2005","journal-title":"J Virol"},{"key":"2022020201071992700_CIT0026","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/S0042-6822(02)00035-1","article-title":"Multiple amino acid residues confer temperature sensitivity to human influenza virus vaccine strains (FluMist) derived from cold-adapted A\/Ann Arbor\/6\/60.","volume":"306","author":"Jin","year":"2003","journal-title":"Virology"},{"key":"2022020201071992700_CIT0027","doi-asserted-by":"crossref","first-page":"4209","DOI":"10.1016\/j.vaccine.2020.04.004","article-title":"Replication of live attenuated influenza vaccine viruses in human nasal epithelial cells is associated with H1N1 vaccine effectiveness.","volume":"38","author":"Hawksworth","year":"2020","journal-title":"Vaccine"},{"key":"2022020201071992700_CIT0028","doi-asserted-by":"crossref","first-page":"eabg7996","DOI":"10.1126\/sciadv.abg7996","article-title":"Immunological and pathological outcomes of SARS-CoV-2 challenge following formalin-inactivated vaccine in ferrets and rhesus macaques.","volume":"7","author":"Bewley","year":"2021","journal-title":"Sci Adv"},{"key":"2022020201071992700_CIT0029","article-title":"COVID-eVax, an electroporated DNA vaccine candidate encoding the SARS-CoV-2 RBD, elicits protective responses in animal models.","author":"Conforti","year":"2021","journal-title":"Mol Ther"},{"key":"2022020201071992700_CIT0030","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1038\/s42003-021-02443-0","article-title":"ChAdOx1 nCoV-19 protection against SARS-CoV-2 in rhesus macaque and ferret challenge models.","volume":"4","author":"Lambe","year":"2021","journal-title":"Commun Biol"},{"key":"2022020201071992700_CIT0031","doi-asserted-by":"crossref","first-page":"103153","DOI":"10.1016\/j.ebiom.2020.103153","article-title":"Prophylactic intranasal administration of a TLR2\/6 agonist reduces upper respiratory tract viral shedding in a SARS-CoV-2 challenge ferret model.","volume":"63","author":"Proud","year":"2021","journal-title":"EBioMedicine"},{"key":"2022020201071992700_CIT0032","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1038\/s41586-020-2739-1","article-title":"The coding capacity of SARS-CoV-2.","volume":"589","author":"Finkel","year":"2021","journal-title":"Nature"},{"key":"2022020201071992700_CIT0033","doi-asserted-by":"crossref","first-page":"e0243597","DOI":"10.1371\/journal.pone.0243597","article-title":"Transmissibility of COVID-19 depends on the viral load around onset in adult and symptomatic patients.","volume":"15","author":"Kawasuji","year":"2020","journal-title":"PLoS One"},{"key":"2022020201071992700_CIT0034","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1093\/infdis\/146.6.780","article-title":"Evaluation of a cold-recombinant influenza virus vaccine in ferrets.","volume":"146","author":"Maassab","year":"1982","journal-title":"J Infect Dis"},{"key":"2022020201071992700_CIT0035","doi-asserted-by":"crossref","first-page":"83","DOI":"10.3389\/fmicb.2018.00083","article-title":"Non-specific effect of vaccines: immediate protection against respiratory syncytial virus infection by a live attenuated influenza vaccine.","volume":"9","author":"Lee","year":"2018","journal-title":"Front Microbiol"},{"key":"2022020201071992700_CIT0036","doi-asserted-by":"crossref","first-page":"8067","DOI":"10.1016\/j.vaccine.2007.09.012","article-title":"Immediate and broad-spectrum protection against heterologous and heterotypic lethal challenge in mice by live influenza vaccine.","volume":"25","author":"Seo","year":"2007","journal-title":"Vaccine"},{"key":"2022020201071992700_CIT0037","doi-asserted-by":"crossref","first-page":"e553","DOI":"10.1542\/peds.2006-2836","article-title":"Trivalent live attenuated intranasal influenza vaccine administered during the 2003-2004 influenza type A (H3N2) outbreak provided immediate, direct, and indirect protection in children.","volume":"120","author":"Piedra","year":"2007","journal-title":"Pediatrics"},{"key":"2022020201071992700_CIT0038","doi-asserted-by":"crossref","first-page":"2865","DOI":"10.1016\/j.vaccine.2010.01.060","article-title":"A whole genome transcriptional analysis of the early immune response induced by live attenuated and inactivated influenza vaccines in young children.","volume":"28","author":"Zhu","year":"2010","journal-title":"Vaccine"},{"key":"2022020201071992700_CIT0039","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1126\/science.abc4262","article-title":"Can existing live vaccines prevent COVID-19?","volume":"368","author":"Chumakov","year":"2020","journal-title":"Science"},{"key":"2022020201071992700_CIT0040","doi-asserted-by":"crossref","first-page":"e00907","DOI":"10.1128\/mBio.00907-20","article-title":"Could an unrelated live attenuated vaccine serve as a preventive measure to dampen septic inflammation associated with COVID-19 infection?","volume":"11","author":"Fidel","year":"2020","journal-title":"mBio"}],"container-title":["The Journal of Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jid\/advance-article-pdf\/doi\/10.1093\/infdis\/jiab594\/42245234\/jiab594.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jid\/article-pdf\/225\/3\/404\/42361157\/jiab594.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jid\/article-pdf\/225\/3\/404\/42361157\/jiab594.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T20:07:49Z","timestamp":1643746069000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jid\/article\/225\/3\/404\/6459422"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12,11]]},"references-count":40,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2021,12,11]]},"published-print":{"date-parts":[[2022,2,1]]}},"URL":"https:\/\/doi.org\/10.1093\/infdis\/jiab594","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/2021.02.01.429110","asserted-by":"object"}]},"ISSN":["0022-1899","1537-6613"],"issn-type":[{"value":"0022-1899","type":"print"},{"value":"1537-6613","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2022,2,1]]},"published":{"date-parts":[[2021,12,11]]}}}